Ratings for Doximity DOCS were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 5 | 9 | 1 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 3 | 6 | 0 | 0 |
| 2M Ago | 0 | 1 | 2 | 1 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $52.93, a high estimate of $75.00, and a low estimate of $33.00. This upward trend is evident, with the current average reflecting a 53.42% increase from the previous average price target of $34.50.
Deciphering Analyst Ratings: An In-Depth Analysis
The perception of Doximity by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Steven Valiquette | Mizuho | Announces | Neutral | $55.00 | - |
| Anne Samuel | JP Morgan | Raises | Neutral | $48.00 | $30.00 |
| David Roman | Goldman Sachs | Announces | Neutral | $58.00 | - |
| Jailendra Singh | Truist Securities | Raises | Hold | $49.00 | $35.00 |
| Ricky Goldwasser | Morgan Stanley | Raises | Equal-Weight | $53.00 | $33.00 |
| Richard Close | Canaccord Genuity | Raises | Hold | $60.00 | $40.00 |
| Stephanie Davis | Barclays | Raises | Overweight | $75.00 | $52.00 |
| Brian Peterson | Raymond James | Raises | Outperform | $65.00 | $37.00 |
| Stan Berenshteyn | Wells Fargo | Raises | Equal-Weight | $41.00 | $19.00 |
| Scott Schoenhaus | Keybanc | Announces | Overweight | $70.00 | - |
| Ricky Goldwasser | Morgan Stanley | Raises | Underweight | $33.00 | $26.00 |
| Stephanie Davis | Barclays | Raises | Overweight | $52.00 | $35.00 |
| Elizabeth Anderson | Evercore ISI Group | Raises | In-Line | $45.00 | $34.00 |
| Allen Lutz | B of A Securities | Raises | Neutral | $45.00 | $32.00 |
| Vikram Kesavabhotla | Baird | Raises | Outperform | $45.00 | $41.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Doximity. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Doximity compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Doximity's stock. This comparison reveals trends in analysts' expectations over time.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Doximity's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Doximity analyst ratings.
Unveiling the Story Behind Doximity
Doximity Inc is a digital platform for U.S. medical professionals. Its cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers.
Doximity's Financial Performance
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Positive Revenue Trend: Examining Doximity's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 20.44% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Doximity's net margin excels beyond industry benchmarks, reaching 32.27%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Doximity's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.71%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Doximity's ROA stands out, surpassing industry averages. With an impressive ROA of 4.03%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Doximity's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analyst Ratings: Simplified
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
